Sarfez Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Vienna VA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2017
NCT03214874
First Marketed Drug
2021
torsemide (demadex)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Sarfez Pharmaceuticals, Inc. | SARFEZ PHARMACEUTICALS INC

Active Ingredients

Marketed Drugs (1)

torsemide (demadex) (2021)

Drugs in Phase 2 Trials (1)

torsemide (demadex) (4 trials)

Drugs in Phase 1 Trials (1)

furosemide (lasix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 1)

Body Weight Changes (Phase 1)

Heart Failure (Phase 1)

Kidney Diseases (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2